- Home
- GMAB vs EIX Comparison
GMAB vs EIX Comparison
Compare GMAB & EIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- EIX
- Stock Information
- Founded
- GMAB 1999
- EIX 1886
- Country
- GMAB Denmark
- EIX United States
- Employees
- GMAB N/A
- EIX N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- EIX Electric Utilities: Central
- Sector
- GMAB Health Care
- EIX Utilities
- Exchange
- GMAB Nasdaq
- EIX Nasdaq
- Market Cap
- GMAB 17.4B
- EIX 21.3B
- IPO Year
- GMAB N/A
- EIX N/A
- Fundamental
- Price
- GMAB $30.40
- EIX $57.92
- Analyst Decision
- GMAB Strong Buy
- EIX Hold
- Analyst Count
- GMAB 6
- EIX 12
- Target Price
- GMAB $40.40
- EIX $65.27
- AVG Volume (30 Days)
- GMAB 2.6M
- EIX 2.8M
- Earning Date
- GMAB 11-06-2025
- EIX 10-28-2025
- Dividend Yield
- GMAB N/A
- EIX 5.72%
- EPS Growth
- GMAB 132.41
- EIX 123.49
- EPS
- GMAB 25.10
- EIX 7.64
- Revenue
- GMAB $3,845,670,022.00
- EIX $18,088,000,000.00
- Revenue This Year
- GMAB $24.92
- EIX $7.30
- Revenue Next Year
- GMAB $15.97
- EIX $2.70
- P/E Ratio
- GMAB $1.21
- EIX $7.58
- Revenue Growth
- GMAB 29.57
- EIX 4.43
- 52 Week Low
- GMAB $17.24
- EIX $47.73
- 52 Week High
- GMAB $33.65
- EIX $88.65
- Technical
- Relative Strength Index (RSI)
- GMAB 57.24
- EIX 60.62
- Support Level
- GMAB $28.08
- EIX $56.21
- Resistance Level
- GMAB $29.35
- EIX $57.30
- Average True Range (ATR)
- GMAB 0.69
- EIX 1.14
- MACD
- GMAB -0.07
- EIX 0.11
- Stochastic Oscillator
- GMAB 98.73
- EIX 84.91
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About EIX Edison International
Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.